Article Text

Download PDFPDF
521 Safety and efficacy of Durvalumab (D) + Tremelimumab (T) + Metronomic Oral Vinorelbine (MOV) in patients with recurrent/metastatic cervical cancer (RMCC) in the MOVIE trial
  1. Jean-Sebastien Frenel1,
  2. Laurent Mathiot1,
  3. Edith Bocorman2,
  4. Alice Hervieu3,
  5. Elodie Coquan4,
  6. Thibault De La Motte Rouge5,
  7. Esma Saada-Bouzid6,
  8. Renaud Sabatier7,
  9. Pernelle Lavaud8,
  10. François Legrand9,
  11. Claire Cropet10,
  12. Emmanuelle Charaffe11 and
  13. Anthony Goncalves11
  1. 1Institut de Cancerologie de L’ouest, Nantes, France
  2. 2Institut Curie, Paris, France
  3. 3Centre Georges François Leclerc, Dijon, France
  4. 4Centre François Baclesse, Caen, France
  5. 5Centre Eugene Marquis, Rennes, France
  6. 6Centre Antoine LAcassagne, Nice, France
  7. 7Institut Paoli-Calmettes, Marseille, France
  8. 8Gustave Roussy, Paris, France
  9. 9Unicancer, Paris, France
  10. 10Centre Léon BERARD, and GINECO, Lyon, France
  11. 11IPC, Marseille, France


Introduction/Background Anti PD-1 are now standard of care in RMCC as 1st or 2nd line therapy. We report updated efficacy and safety results of triplet therapy combining D+T+ MOV in the RMCC cohort of the MOVIE trial.

Methodology This phase 1/2 study combined +D (1500 mg Q4W IV, for up to 26 cycles) + T (75 mg Q4W IV, for up to 4 cycles) + MOV (40 mg thrice weekly, until disease progression) in several cohorts. Primary endpoint of phase 2 part was the clinical benefit rate (CBR) at 24 weeks according to RECIST 1.1. criteria.

Results In total, 31/32 RMCC patients were evaluable. Median number of previous lines of chemotherapy (CT) for metastatic disease was 2 (0–6) with 12/31 (38.7%) patients pre-treated with bevacizumab. Previous anti PD(L)1 was not allowed. CBR was reported at ESMO 2021. Objective responses were observed regardless of tumor PD-L1. All efficacy endpoints are reported on table 1. After a median follow-up of 26.8 months (Q1-Q3: 9.2–35.5), 27 pts (87.1%) had discontinued treatment for progression (n=17, 54.8%), toxicity (n=5, 16.1%), physician or patient decision (n=4), or standard treatment duration (n=1). Grade ≥ 3 immune related TRAEs occurred in 13 patients (41.9%) (including 2 grade III colitis) and grade ≥ 3 chemotherapy-TRAEs (including 3 grade III febrile neutropenia) occurred in 13 patients (41.9%). No grade 5 AE were reported.

Abstract 521 Table 1

Conclusion Adding MOV to double immune therapy (D+T) for the treatment of RMCC patients produced clinically meaningful response particularly in PDL1+ population. Toxicity is significant but manageable.

Disclosures None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.